Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
Authors
Keywords
Colorectal cancer, Adjuvant chemotherapy, Modified FOLFOX6, Capecitabine, Oxaliplatin, Prognosis, KRAS, Microsatellite instability
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-05-09
DOI
10.1186/s12885-015-1406-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial
- (2014) D. Klingbiel et al. ANNALS OF ONCOLOGY
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
- (2013) Dmitri Mouradov et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
- (2013) Vlad Popovici et al. BMC CANCER
- KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
- (2013) A I Phipps et al. BRITISH JOURNAL OF CANCER
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
- (2013) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Molecular Dissection of Microsatellite Instable Colorectal Cancer
- (2013) Eduardo Vilar et al. Cancer Discovery
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Role of microsatellite instability in the management of colorectal cancers
- (2012) Bruno Buecher et al. DIGESTIVE AND LIVER DISEASE
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
- (2012) Aimery de Gramont et al. LANCET ONCOLOGY
- Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
- (2011) C. Twelves et al. ANNALS OF ONCOLOGY
- Adjuvant therapy in colon cancer
- (2011) Janet S Graham et al. Expert Review of Anticancer Therapy
- Oxaliplatin As Adjuvant Therapy for Colon Cancer: Updated Results of NSABP C-07 Trial, Including Survival and Subset Analyses
- (2011) Greg Yothers et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer
- (2011) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Postoperative Adjuvant Chemotherapy for Stage II Colorectal Cancer: A Systematic Review of 12 Randomized Controlled Trials
- (2011) Xiaojian Wu et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting
- (2009) Lucia I. H. Overbeek et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers
- (2008) Annegret Müller et al. VIRCHOWS ARCHIV
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started